IC
IART icon

Innealta Capital’s Integra LifeSciences IART Stock Holding History

Innealta Capital’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-807
Closed -$23.5K – 867
2024
Q2 		$23.5K Buy
+807
New +$23.9K 0.01% 594

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Innealta Capital's IART Position: Q3 2024 in Review

Innealta Capital sold out of Integra LifeSciences (IART) in Q3 2024, closing a stake of 807 shares — an estimated $23.5K sold.

Innealta Capital first reported a position in IART in Q2 2024 and held it in 1 quarter. The position peaked at $23.5K in Q2 2024. 225 funds tracked by Wall St. Rank hold IART as of Q3 2024.

  • Innealta Capital reported no remaining Integra LifeSciences position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 807 Integra LifeSciences shares in Q3 2024, an estimated $23.5K.
  • Innealta Capital first reported a position in Integra LifeSciences in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Integra LifeSciences position peaked at $23.5K in Q2 2024.
  • 225 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.